Company intelligence
Presbyterian Healthcare Services
Presbyterian exists to improve the health of the patients, members and communities we serve. Since 1908.
About Presbyterian Healthcare Services
Presbyterian Healthcare Services exists to improve the health of patients, members and the communities we serve. We are a locally owned, not-for-profit healthcare system of nine hospitals, a statewide health plan and a growing multi-specialty medical group. Founded in New Mexico in 1908, we are the state’s largest private employer with nearly 14,000 employees – including more than 1,600 providers and nearly 4,700 nurses. Our health plan serves more than 580,000 members statewide and offers Medicare Advantage, Medicaid (Turquoise Care) and Commercial health plans.
Verified activity
Signals from Presbyterian Healthcare Services
19 published signals
Presence & Recognition
Presbyterian Healthcare Services recognizes and celebrates the Presbyterian team members who serve New Mexicans with compassion, expertise, and an unwavering commitment to improving health and well-being across the state.
Reported by Presbyterian Healthcare Services
Research & Knowledge
Presbyterian Healthcare Services highlights SANOVO, which reports upfront osimertinib plus savolitinib improved PFS in EGFR-mutant, MET-expressing NSCLC.
Reported by Munoh Kenne Foma , MD, MPH
Research & Knowledge
Presbyterian Healthcare Services highlights HARMONi-2, which reports a statistically significant overall survival advantage for Ivonescimab over pembrolizumab in first-line PD-L1–positive advanced NSCLC.
Reported by Munoh Kenne Foma , MD, MPH
Research & Knowledge
Presbyterian Healthcare Services highlights Daraxonrasib, which demonstrates promising activity across non-G12C RAS-mutant NSCLC including KRAS G12D, G12V, and G12A.
Reported by Munoh Kenne Foma , MD, MPH
Products & Services
Presbyterian Healthcare Services launched two new Mobile Health Clinics in New Mexico to bring care closer to communities and expand access for those who need it most.
Reported by Presbyterian Healthcare Services
Operations & Supply
Presbyterian Healthcare Services launched two new Mobile Health Clinics based in Albuquerque and Las Cruces to bring care closer to communities across New Mexico.
Reported by Rishi Sikka, M.D.
Research & Knowledge
Presbyterian Healthcare Services highlighted that TALENTACE, combining TACE with atezolizumab and bevacizumab, strengthens the integration of locoregional and systemic therapy in hepatocellular cancer.
Reported by Munoh Kenne Foma , MD, MPH
Research & Knowledge
Presbyterian Healthcare Services highlighted that HCC treatment allocation is becoming multidisciplinary as the boundaries between surgery, locoregional therapy, radiation, and systemic therapy evolve.
Reported by Munoh Kenne Foma , MD, MPH
Research & Knowledge
Presbyterian Healthcare Services highlighted that Daraxonrasib, a RAS-targeted therapy, establishes a new treatment pathway in metastatic pancreatic cancer with a survival benefit in RASolute 302.
Reported by Munoh Kenne Foma , MD, MPH
Research & Knowledge
Presbyterian Healthcare Services noted that HERIZON-GEA-01, a Zanidatamab-based therapy, introduces a new first-line HER2-directed strategy for gastric/GEJ/esophageal adenocarcinoma.
Reported by Munoh Kenne Foma , MD, MPH
Research & Knowledge
Presbyterian Healthcare Services noted that the termination of the personalized mRNA vaccine trial for colorectal cancer highlights the importance of MRD identification.
Reported by Munoh Kenne Foma , MD, MPH
Products & Services
Presbyterian Healthcare Services launched two state-of-the-art mobile clinics in New Mexico.
Reported by Brian Brown, CHIE, PAHM
Operations & Supply
Presbyterian Healthcare Services is bringing two brand new mobile health clinics to New Mexicans.
Reported by Presbyterian Healthcare Services
Research & Knowledge
Presbyterian Healthcare Services noted PATINA strengthening chemotherapy-free HER2/ER/CDK4/6 maintenance in HR+/HER2+ metastatic disease.
Reported by Munoh Kenne Foma , MD, MPH
Research & Knowledge
Presbyterian Healthcare Services noted Gedatolisib advancing in PIK3CA-mutant HR+/HER2 disease.
Reported by Munoh Kenne Foma , MD, MPH
Research & Knowledge
Presbyterian Healthcare Services noted ESR1 ctDNA testing becoming increasingly important at endocrine progression.
Reported by Munoh Kenne Foma , MD, MPH
Research & Knowledge
Presbyterian Healthcare Services noted DESTINY-Breast05/11 reinforcing T-DXd as a major advance in early HER2+ breast cancer.
Reported by Munoh Kenne Foma , MD, MPH
Research & Knowledge
Presbyterian Healthcare Services noted ASCENT-03/04 moving sacituzumab govitecan into first-line metastatic TNBC.
Reported by Munoh Kenne Foma , MD, MPH
Research & Knowledge
Presbyterian Healthcare Services highlighted new ASCO guidance for stage I–III HR+/HER2− breast cancer emphasizing risk-adapted treatment rather than stage alone.
Reported by Munoh Kenne Foma , MD, MPH